Yahoo Canada Web Search

Search results

1. www.jidsponline.org › article › S1087-0024(20)30005JAK Inhibitors for the Treatment of Pediatric Alopecia Areata

   www.jidsponline.org › article › S1087-0024(20)30005

   Alopecia areata is a common autoimmune condition that disproportionately affects children and can significantly hinder quality of life. Few safe and effective therapies are available for the treatment of severely affected pediatric patients. JAK inhibitors have been recently established as an effective and well-tolerated therapy in adults, but there are limited data regarding the use of JAK ...

   • Author: Claire E. Hamilton, Brittany G. Craiglow

   • Publish Year: 2020

2. www.naaf.org › watch-learn › whats-new-in-pediatricWhat’s New In Pediatric Alopecia Areata Treatment?

   www.naaf.org › watch-learn › whats-new-in-pediatric

   • Cached

   In 2023, the FDA approved the first treatment for alopecia areata in adolescents. Pediatric dermatologist Brittany Craiglow, MD, will bring us up to date on alopecia areata in children and the current treatment landscape. Note on clinical trials: Dr. Craiglow discussed clinical trial participation in her presentation.

3. www.ncbi.nlm.nih.gov › pmc › articlesBaricitinib for the Treatment of Alopecia Areata - PMC

   www.ncbi.nlm.nih.gov › pmc › articles

   May 17, 2023 · Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss that can affect any hair-bearing site [1]. AA clinical presentation is significantly heterogeneous. Classically, AA presents as a single or multiple asymptomatic, well-demarcated, circular, and smooth patches of hair loss [1].

4. Videos

   • 

     2:41

     youtube.com

     Alopecia Areata in Children - Causes, Signs & Treatment

     Aug 2, 2019

     62.7K Views

   • 

     2:04

     youtube.com

     Baricitinib for Alopecia | NEJM

     May 5, 2022

     18.6K Views

   • 

     9:37

     youtube.com

     Hair Loss Drug to Cure MY BALDNESS | Alopecia Areata Cure

     Jul 15, 2022

     1.1M Views

   View all

5. trials.lilly.com › en-US › trialA Study of Baricitinib (LY3009104) in Children From 6 Years ...

   trials.lilly.com › en-US › trial

   • Cached

   A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) I4V-MC-JAIO - ClinicalTrials.gov - NCT05723198 The main purpose of the study is to assess efficacy and safety of Baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.

6. link.springer.com › article › 10Baricitinib for the Treatment of Alopecia Areata | Drugs

   link.springer.com › article › 10

   • Cached

   May 17, 2023 · Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss that can affect any hair-bearing site. AA clinical presentation is heterogeneous. Its pathogenesis involves immune and genetic factors and several pro-inflammatory cytokines involved in AA pathogenesis, including interleukin-15 and interferon-γ, as well as Th2 cytokines ...

7. onlinelibrary.wiley.com › doi › 10Improvement of severe alopecia areata in an adolescent ...

   onlinelibrary.wiley.com › doi › 10

   Dec 27, 2023 · Recently, alopecia areata (AA) treatment via the Janus kinase (JAK)-signal transducer and activator of transcription pathway has been reported. However, as baricitinib, a JAK1/2 inhibitor is only approved for adult patients, children, and adolescent patients still lack treatment options.

8. People also ask

   Does baricitinib treat alopecia areata?

   • On the basis of BRAVE-AA1 and BRAVE-AA2 results, baricitinib was recently approved by the EMA and US FDA for the treatment of adults with severe AA. Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss that can affect any hair-bearing site .

   Baricitinib for the Treatment of Alopecia Areata - PMC

   www.ncbi.nlm.nih.gov/pmc/articles/PMC10191081/

   See all results for this question

   Can ruxolitinib be used to treat alopecia areata in pediatric hematopoietic?

   • Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Alopecia areata prevalence by gender and age.

   JAK Inhibitors for the Treatment of Pediatric Alopecia Areata

   www.jidsponline.org/article/S1087-0024(20)30005-8/fulltext

   See all results for this question

   Can baricitinib be used for hair loss?

   • BRAVE-AA1 (NCT03570749), a phase 2/3 adaptive, placebo (PBO)-controlled, double-blind trial, evaluated the efficacy and safety of oral baricitinib in patients with AA who had ≥ 50% scalp hair loss.

   Baricitinib for the Treatment of Alopecia Areata | Drugs - Springer

   link.springer.com/article/10.1007/s40265-023-01873-w

   See all results for this question

   Is baricitinib better than placebo for hair growth?

   • Baricitinib was shown to be superior to placebo for hair growth after 36 weeks of treatment in adults with severe AA in a phase 2 trial and recently in two phase 3 trials (BRAVE-AA1 and BRAVE-AA2). On the basis of BRAVE-AA1 and BRAVE-AA2 results, baricitinib was recently approved by the EMA and US FDA for the treatment of adults with severe AA.

   Baricitinib for the Treatment of Alopecia Areata - PMC

   www.ncbi.nlm.nih.gov/pmc/articles/PMC10191081/

   See all results for this question

   Does ruxolitinib treat alopecia areata?

   • Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. Ruxolitinib for the treatment of severe alopecia areata. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families.

   JAK Inhibitors for the Treatment of Pediatric Alopecia Areata

   www.jidsponline.org/article/S1087-0024(20)30005-8/fulltext

   See all results for this question

9. www.nejm.org › doi › fullTwo Phase 3 Trials of Baricitinib for Alopecia Areata

   www.nejm.org › doi › full

   Mar 26, 2022 · Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report, Dermatology The American Medical Journal, (2024). https://doi.org ...